Posts tagged degenerative brain diseases
IntelGenx initiates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (OTCQX:IGXT; TSXV:IGX) has initiated the Phase 2a proof-of- concept clinical trial with its Montelukast VersaFilm in Alzheimer’s disease patients, following clearance by Health Canada. 

Read More
IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

IntelGenx (OTCQX:IGXT; TSXV:IGX) submitted a clinical trial application to Health Canada for approval to initiate a Phase 2a proof-of-concept study with montelukast in mild-to-moderate Alzheimer's disease (AD). 

Read More